Feature | EP Lab | May 15, 2015

Remote Monitoring Recommended by HRS to Become Standard of Care

International panel of experts advocates for continuous monitoring supplemented with annual in-person appointments

HRS, remote monitoring, RM, standard of care, CIEDs

May 15, 2015 — A new expert consensus statement by the Heart Rhythm Society (HRS) recommends remote monitoring (RM) become standard of care for patients with cardiovascular implantable electronic devices (CIEDs). The HRS Expert Consensus Statement on Remote Interrogation and Monitoring for Cardiovascular Electronic Implantable Devices was written by an international group of experts and published online in HeartRhythm Journal, the official journal of HRS. This new approach presents a new paradigm for managing patients with CIEDs and will be presented at Heart Rhythm 2015, the Heart Rhythm Society’s 36th Annual Scientific Sessions.

Over the past decade, novel technologies have created the ability for devices to monitor their own function, record arrhythmias and communicate this information to healthcare providers without participation of the patient. Enrollment in RM has become accessible to all patients and allows doctors to monitor a patient’s device between follow-up visits and alerts them to any issues via wireless technology.

The new expert consensus statement builds upon the 2008 HRS/EHRA Expert Consensus on the Monitoring of Cardiovascular Implantable Electronic Devices (CIEDs), and reinforces the need for consistent follow-up and outlines the limitations of in-person-only follow-up. The writing group focuses on the organizational change required to most effectively implement RM by replacing the occasional, routine appointment to a system of nearly continuous monitoring, making it more convenient and efficient for the patient and healthcare provider. Recommendations also include that the patient have an in-person evaluation at the physician’s office in response to alert notifications communicated by RM.

“We’ve seen firsthand how the constant and continuous communication between the patient’s device and the healthcare provider is improving the quality and efficiency of care. There are proven advantages for the patient and we outline a specific strategy on how remote monitoring can benefit both patients and providers,” said task force chair and lead author of the statement, David Slotwiner, M.D.,FHRS,  Hofstra School of Medicine, North Shore-Long Island Jewish Health in New Hyde Park, New York. “We hope that this type of wireless, remote monitoring that provides real-time insights to the patient’s healthcare team can become a model for managing other chronic conditions.”

Key recommendations within the expert consensus statement include the following:

  • Remote monitoring should be combined with at least an annual in-person evaluation and all patients with CIEDs should be offered remote monitoring as part of the standard follow-up management strategy;
  • Before implementing RM, it is recommended that each patient be educated about the nature of RM, responsibilities and expectations, potential benefits, limitations and an explanation of how RM information may be used;
  • All CIEDs be checked through direct patient contact 2-12 weeks after being implanted; and
  • Have specific policies in place to govern program operations, roles and responsibilities of those involved and the expected timelines for service provision.

 

The expert consensus statement was developed in collaboration with the American College of Cardiology (ACC), Pediatric & Congenital Electrophysiology Society (PACES), the American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), the European Heart Rhythm Association (EHRA) and Latin American Society of Cardiac Pacing and Electrophysiology (Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología, SOLAECE).   

For more information: www.hrsonline.org

Related Content

Earlier this year, Medtronic began a worldwide pivotal study evaluating its investigational Extravascular Implantable Cardioverter Defibrillator (EV ICD) system to treat dangerously fast heart rhythms. The EV ICD system is designed to deliver lifesaving defibrillation and pacing therapy via a device the same size as traditional, transvenous ICDs, but with a lead (thin wire) placed outside the heart and veins. The future of CRM device technology.

Earlier this year, Medtronic began a worldwide pivotal study evaluating its investigational Extravascular Implantable Cardioverter Defibrillator (EV ICD) system to treat dangerously fast heart rhythms. The EV ICD system is designed to deliver lifesaving defibrillation and pacing therapy via a device the same size as traditional, transvenous ICDs, but with a lead (thin wire) placed outside the heart and veins.

Feature | EP Lab | November 11, 2019 | Hrishikesh Kadam
Cardiac rhythm management (CRM) devices in use today are evolving to raise the bar beyond monitoring and managing car
A comparison between the EPstar 2F and 6F catheters from Baylis. Electrophysiology catheters. EP lab

A comparison between the EPstar 2F and 6F catheters from Baylis.

News | EP Lab | October 31, 2019
October 31, 2019 — Baylis Medical announced the first North American use of its EPstar Fixed...
New Study Shows Chronic Epilepsy Associated With Marker of Cardiac Electrical Instability
News | EP Lab | October 24, 2019
LivaNova PLC announced the publication of a new study in Neurology, which suggests that chronic epilepsy may be...
Lenox Hill Hospital Opens New Heart Rhythm Center
News | EP Lab | August 27, 2019
Lenox Hill Hospital (New York, N.Y.) has established a brand new Heart Rhythm Center dedicated to the treatment of...
Damaged Hearts Rewired With Nanotube Fibers

Researchers at Texas Heart Institute and Rice University have confirmed that flexible, conductive fibers made of carbon nanotubes can bridge damaged tissue to deliver electrical signals and keep hearts beating despite congestive heart failure or dilated cardiomyopathy or after a heart attack. Image courtesy of Texas Heart Institute.

News | EP Lab | August 15, 2019
Thin, flexible fibers made of carbon nanotubes have now proven able to bridge damaged heart tissues and deliver the...
Cardiac Device Complications Vary Widely Among Hospitals
News | EP Lab | July 31, 2019
The chances of patients experiencing complications after having a cardiac device implanted vary according to where they...
A new infection risk scoring system has been developed based on data from the large PADIT Trial.[1] The new scoring system was presented as a follow up to that study during a late-breaking session at Heart Rhythm 2019, the Heart Rhythm Society's 40th Annual Scientific Sessions.

Figure 1: The PADIT infection risk score ranging from 0 to 14 points classified patients into three risk groups, low (0-4), intermediate (5-6) and high (≥7). The risk groups had rates of hospitalization for infection of 0.51%, 1.42% and 3.41%, respectively 

News | EP Lab | May 15, 2019
May 15, 2019 — A new infection risk scoring system has been developed based on data from the large PADIT Trial.[1] Th
Studies Find Race and Gender Disparities in Implantable Heart Devices
News | EP Lab | May 15, 2019
May 15, 2019 - Three new studies show that patients who are medically indicated for implantable heart devices, includ
Overlay Init